Lv2
200 积分 2025-05-27 加入
A first-in-class oral clinical candidate targeting MLLT1 and 3 degradation for the treatment of advanced AML and ALL including menin inhibitor resistant / refractory disease
29天前
已关闭
Psychedelics elicit their effects by 5-HT2A receptor-mediated Gi signalling
1个月前
已完结
Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders
3个月前
已完结
Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor
3个月前
已完结
MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition
3个月前
已完结
Kartogenin Enhanced Chondrogenesis in Cocultures of Chondrocytes and Bone Mesenchymal Stem Cells
8个月前
已完结
皖公网安备34019202002308
